Potent predictive CpG signature for temozolomide response in non-glioma-CpG island methylator phenotype glioblastomas with methylated MGMT promoter.
Sign Up to like & getrecommendations! Published in 2022 at "Epigenomics"
DOI: 10.2217/epi-2022-0344
Abstract: Aim: We aimed to identify potent CpG signatures predicting temozolomide (TMZ) response in glioblastomas (GBMs) that do not have the glioma-CpG island methylator phenotype (G-CIMP) but have a methylated promoter of MGMT (meMGMT). Materials &… read more here.
Keywords: cpg island; methylator phenotype; glioma cpg; response ... See more keywords